Descriptors and administrative fields exactly as published in the CMS HCPCS quarterly file.
Billing context: J-codes
Units are reported in multiples of the dosage in the code descriptor.
One HCPCS billing unit of J1958
5 MG
Medicare payment limit per unit (Q4 2026): $0.033
No published MUE for J1958. CMS keeps some MUE values confidential, so this does not mean there is no daily unit limit.
Medicare Part B drug payment limits per billing unit, by quarter, from the CMS payment limit (ASP) files.
Current Medicare Part B payment limit · Q4 2026
$0.033per 5 MG
Effective Oct 1, 2026 – Dec 31, 2026 · ASP methodology (per CMS file) · based on Q2 2026 ASP data · coinsurance 20.000%
CMS note: “Added October 2026”
| Quarter | Effective | Payment limit | Per (billing unit) | Coinsurance | Change | CMS notes |
|---|---|---|---|---|---|---|
| Q4 2026 | Oct 1, 2026 – Dec 31, 2026 | $0.033 | 5 MG | 20% | — | Added October 2026 |
Medicare hospital outpatient (OPPS) · Q4 2026
N Packaged: no separate payment
Washington Apple Health · professional claims
AAC = actual acquisition cost, based on NDC or invoice; BR = by report; NC = not covered; DC = not covered, see a different code; DP = covered under another program (see comments); PA = prior authorization; EPA = expedited prior authorization (see the billing guide); CPA = contractor prior authorization (Qualis). For professional claims; hospital-administered drugs are paid under HCA's outpatient (OPPS/EAPG) rules.
Packages CMS assigns to this code in its NDC–HCPCS crosswalks, with billable units per package. Only official crosswalk rows are shown.
| NDC (11-digit) | CMS drug name · labeler | Pkg size × qty | Units / item | Units / NDC | Derived $ / NDC | Crosswalk | Quarters | FDA listing |
|---|---|---|---|---|---|---|---|---|
| 00264-1009-90 | LevetiracetamB. Braun Medical Inc. | 100 × 24 | 200 | 4,800 | $158.40 | ASP | Q4 2026 | ListedLevetiracetam |
| 00264-1509-90 | LevetiracetamB. Braun Medical Inc. | 100 × 24 | 300 | 7,200 | $237.60 | ASP | Q4 2026 | ListedLevetiracetam |
| 00264-5009-90 | LevetiracetamB. Braun Medical Inc. | 100 × 24 | 100 | 2,400 | $79.20 | ASP | Q4 2026 | ListedLevetiracetam |
| 36000-0352-40 | LevetiracetamBaxter Healthcare Corporation | 100 × 24 | 100 | 2,400 | $79.20 | ASP | Q4 2026 | ListedLevetiracetam |
| 36000-0354-40 | LevetiracetamBaxter Healthcare Corporation | 100 × 24 | 300 | 7,200 | $237.60 | ASP | Q4 2026 | ListedLevetiracetam |
| 36000-0356-40 | LevetiracetamBaxter Healthcare Corporation | 100 × 24 | 200 | 4,800 | $158.40 | ASP | Q4 2026 | ListedLevetiracetam |
| 65145-0173-10 | LevetiracetamCaplin Steriles USA Inc. | 100 × 10 | 100 | 1,000 | $33.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 65145-0174-10 | LevetiracetamCaplin Steriles USA Inc. | 100 × 10 | 200 | 2,000 | $66.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 65145-0175-10 | LevetiracetamCaplin Steriles USA Inc. | 100 × 10 | 300 | 3,000 | $99.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 43598-0635-10 | LevetiracetamDr. Reddy's Laboratories Inc. | 100 × 10 | 100 | 1,000 | $33.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 43598-0636-10 | LevetiracetamDr. Reddy's Laboratories Inc. | 100 × 10 | 200 | 2,000 | $66.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 43598-0637-10 | LevetiracetamDr. Reddy's Laboratories Inc. | 100 × 10 | 300 | 3,000 | $99.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 43598-0755-10 | LevetiracetamDr. Reddy's Laboratories Inc. | 100 × 10 | 100 | 1,000 | $33.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 43598-0757-10 | LevetiracetamDr. Reddy's Laboratories Inc. | 100 × 10 | 200 | 2,000 | $66.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 43598-0759-10 | LevetiracetamDr. Reddy's Laboratories Inc. | 100 × 10 | 300 | 3,000 | $99.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 55150-0246-47 | LevetiracetamEugia US LLC | 100 × 10 | 100 | 1,000 | $33.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 55150-0247-47 | LevetiracetamEugia US LLC | 100 × 10 | 200 | 2,000 | $66.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 55150-0248-47 | LevetiracetamEugia US LLC | 100 × 10 | 300 | 3,000 | $99.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 65219-0042-71 | LevetiracetamFreseniUS Kabi USA, LLC | 100 × 24 | 100 | 2,400 | $79.20 | ASP | Q4 2026 | ListedLevetiracetam |
| 65219-0044-71 | LevetiracetamFreseniUS Kabi USA, LLC | 100 × 24 | 200 | 4,800 | $158.40 | ASP | Q4 2026 | ListedLevetiracetam |
| 65219-0046-71 | LevetiracetamFreseniUS Kabi USA, LLC | 100 × 24 | 300 | 7,200 | $237.60 | ASP | Q4 2026 | ListedLevetiracetam |
| 00143-9281-10 | LevetiracetamHikma Pharmaceuticals USA Inc. | 100 × 10 | 100 | 1,000 | $33.00 | ASP | Q4 2026 | ListedLevetiracetam in Sodium Chloride |
| 00143-9282-10 | LevetiracetamHikma Pharmaceuticals USA Inc. | 100 × 10 | 200 | 2,000 | $66.00 | ASP | Q4 2026 | ListedLevetiracetam in Sodium Chloride |
| 00143-9283-10 | LevetiracetamHikma Pharmaceuticals USA Inc. | 100 × 10 | 300 | 3,000 | $99.00 | ASP | Q4 2026 | ListedLevetiracetam in Sodium Chloride |
| 67457-0255-10 | LevetiracetamMylan Institutional LLC | 100 × 10 | 100 | 1,000 | $33.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 67457-0265-10 | LevetiracetamMylan Institutional LLC | 100 × 10 | 200 | 2,000 | $66.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 67457-0266-10 | LevetiracetamMylan Institutional LLC | 100 × 10 | 300 | 3,000 | $99.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 14789-0110-05 | LevetiracetamNexus Pharmaceuticals, LLC | 100 × 10 | 100 | 1,000 | $33.00 | ASP | Q4 2026 | ListedLevetiracetam in Sodium Chloride |
| 14789-0220-10 | LevetiracetamNexus Pharmaceuticals, LLC | 100 × 10 | 200 | 2,000 | $66.00 | ASP | Q4 2026 | ListedLevetiracetam in Sodium Chloride |
| 14789-0330-15 | LevetiracetamNexus Pharmaceuticals, LLC | 100 × 10 | 300 | 3,000 | $99.00 | ASP | Q4 2026 | ListedLevetiracetam in Sodium Chloride |
| 25021-0793-82 | LevetiracetamSagent Pharmaceuticals | 100 × 10 | 100 | 1,000 | $33.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 25021-0794-82 | LevetiracetamSagent Pharmaceuticals | 100 × 10 | 200 | 2,000 | $66.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 25021-0795-82 | LevetiracetamSagent Pharmaceuticals | 100 × 10 | 300 | 3,000 | $99.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 70069-0845-10 | LevetiracetamSomerset Pharma, LLC | 100 × 10 | 100 | 1,000 | $33.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 70069-0846-10 | LevetiracetamSomerset Pharma, LLC | 100 × 10 | 200 | 2,000 | $66.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 70069-0847-10 | LevetiracetamSomerset Pharma, LLC | 100 × 10 | 300 | 3,000 | $99.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 44567-0501-10 | LevetiracetamWG Critical Care, LLC | 100 × 10 | 100 | 1,000 | $33.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 44567-0501-90 | LevetiracetamWG Critical Care, LLC | 100 × 10 | 100 | 1,000 | $33.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 44567-0502-10 | LevetiracetamWG Critical Care, LLC | 100 × 10 | 200 | 2,000 | $66.00 | ASP | Q4 2026 | ListedLevetiracetam |
| 44567-0503-10 | LevetiracetamWG Critical Care, LLC | 100 × 10 | 300 | 3,000 | $99.00 | ASP | Q4 2026 | ListedLevetiracetam |
Derived calculation “Derived $ / NDC” = billable units per NDC × the current payment limit. It is arithmetic for orientation, not a payment amount.
Medicare coverage is set nationally (NCDs) and by each Medicare Administrative Contractor (LCDs and Billing & Coding articles). These links open the official documents.
Verification neededCodeRx links to coverage documents instead of copying them: CMS distributes their code lists under AMA, ADA, and AHA license terms that limit reuse. Medicare Advantage, Medicaid, and commercial plans set their own coverage and prior-authorization rules.
Changes detected between the CMS quarterly HCPCS files CodeRx has imported.
| Quarterly file | Change | CMS action code | Details |
|---|---|---|---|
| Q4 2026 | Added to HCPCS | A — Added | Added date Oct 1, 2026 |
All imported releases, checksums, and import reports are listed on the data sources page.
Disclaimer. This application provides informational coding and reimbursement reference data. It does not constitute legal, clinical, coding, or billing advice. Codes, payment amounts, payer rules, and coverage policies can change. Verify all information with current CMS publications, the applicable payer, and your organization’s compliance policies before submitting a claim. CodeRx is not affiliated with or endorsed by CMS, FDA, Medicare, or any payer.